September 27, 2011 — AccessClosure Inc. announced the shipment of its one millionth Mynx unit. The Mynx Vascular Closure Device received U.S. Food and Drug Administration (FDA) approval in May 2007, following with its full commercial launch in September 2007.
Physician feedback attributes the achievement of this milestone to the fact that the Mynx sealant is extravascular, bio-inert and non-thrombogenic, while leaving nothing behind intra-arterially.
In addition, increased patient comfort continues to be one of the top selection criteria in choosing the Mynx. Results from a recent prospective, randomized study indicate a significant reduction in pain with the Mynx when compared to competitive devices. The study found 88 percent of patients considered closure the most painful part of the procedure when a competitive device was used; this was compared to 34 percent of patients when the Mynx was used.
Also contributing to the overall success of Mynx is the continued expansion of its distribution network through international markets. This was demonstrated most recently with the announcement of the Biosensors International distribution agreement throughout the United Kingdom, Switzerland and France. The Mynx is now available through a wide global network of distributors, complementing its direct sales presence in the United States.
For more information: www.accessclosure.com